非瓣膜性心房颤动患者CHA2DS2-VASc评分与左心耳功能关系的研究

殷玉梅; 费晓棠; 刘磊

doi:10.13201/j.issn.1001-1439.2016.04.027

非瓣膜性心房颤动患者CHA2DS2-VASc评分与左心耳功能关系的研究

- 山东省青岛市市南区人民医院内科(山东青岛, 266002)

详细信息

通讯作者: 殷玉梅,E-mail:medyyumei@163.com

中图分类号: R541.7

收稿日期: 2015-11-10

Correlative analysis of CHA2DS2-VASc score and left atrial appendage function in patients with nonvalvular atrial fibrillation

- Department of Cardiology, Shinan People's Hospital, Qingdao, Shandong, 266002, China

More Information

Corresponding author: YIN Yumei, E-mail: medyyumei@163.com

Received Date: 10 November 2015

摘要

- 心房颤动 /
- CHA2DS2-VASc评分 /
- 非瓣膜 /
- 左心耳
Abstract: In this study, we discussed the correlation of CHA2DS2-VASc score and left atrial appendage function in patients with non-valvular atrial fibrillation(AF). From March 2013 to April 2015, 150 patients were hospitalized and diagnosed as AF by dynamic electrocardiogram, of which 95 were persistent AF and 55 were non-persistent AF. CHA2DS2-VASc score was obtained according to their general data and medical history. And TEE was used to assess the diameter of the systolic LAA orifice and left atrial appendage peak emptying flow velocity during diastolic phase. Values were compared and analyzed by statistical software. The 6 out of 150 or 4% patients obtained a high CHA2DS2-VASc score (>6 points), and 68 patients (45.3%) scored low (≤ 3points); there were 76 patients who scored 4 to 6 points, accounting for 50.7%. Compared with non-persistent AF patients, The CHA2DS2-VASc score of the patients with persistent AF was significantly higher, and their systolic LAA orifice was markedly larger with a remarkably reduced left atrial appendage peak emptying flow velocity during diastolic phase. Further, left atrial appendage thrombosis occurred in 8 persistent AF and 3 non-persistent AF patients; Spontaneous echocardiographic contrast was observed in 12 persistent AF patients and 8 non-persistent patients.
- atrial fibrillation /
- CHA2DS2-VASc score /
- non-valvular /
- left atrial appendage

HTML全文

参考文献(12)

[1]	DEMIR K, CAN L, KOC F, et al.Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy[J].Med Princ Pract, 2011, 20:464-469.
[2]	AMIN H, NOWAK R J, SCHINDLER J L.Cardioembolic stroke:practical considerations for patient risk management and secondary prevention[J].Postgrad Med, 2014, 126:55-65.
[3]	FANG M C, GO A S, CHANG Y, et al.Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation[J].J Am Coll Cardiol, 2008, 51:810-815.
[4]	CAMM A J, KIRCHHOF P, LIP G Y, et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology[J].Europace, 2010, 12:1360-1420.
[5]	HUNT S A, ABRAHAM W T, CHIN M H, et al.2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation[J].J Am Coll Cardiol, 2009, 53:1-90.
[6]	MULDER B A, VAN VELDHUISEN D J, CRIJNS H J, et al.Digoxin in patients with permanent atrial fibrillation:data from the RACE II study[J].Heart Rhythm, 2014, 11:1543-1550.
[7]	MAGNANI J W, RIENSTRA M, LIN H, et al.Atrial fibrillation:Current knowledge and future directions in epidemiology and genomics[J].Circulation, 2011, 124:1982-1993.
[8]	QAMRUDDIN S, SHINBANE J, SHRIKI J, et al.Left atrial appendage:struoture, function, imaging modalities and thempoutic options[J].Expert Rev Cardiovasc Ther, 2010, 8:65-75.
[9]	ABHAYARATNA W P, SEWARD J B, APPLETON C P, et al.Left atrial size:physiologic determinants and clinical applications[J].J Am Coll Cardiol, 2006, 47:2357-2363.
[10]	PIYASKULKAEW C, SINGH T, SZPUNAR S, et al.CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation:a pilot study from a single center of the NCDR-PINNACLE registry[J].J Thromb Thrombolysis, 2014, 37:400-403.
[11]	OLESEN J, LIP G Y, HANSEN M L, et al.Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation:a nationwide cohort study[J].BMJ, 2011, 342:d124-126.
[12]	JANUARY C T, WANN L S, ALPERT J S, et al.2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].Circulation, 2014, 130:2071-104.